搜尋
艾伯維
ABBV添加自選
248.050USD
-0.030-0.01%
收盤 07/13, 16:00（美東）報價延遲15分鐘
438.16B總市值
122.10本益比TTM
關於 艾伯維 公司
艾伯維為一家多元、科研驅動的生物製藥領跑者，專注藥物與療法的研發、生產、商業化與銷售。公司透過遍布美洲、歐洲與亞洲的生產與行銷渠道，將療法推向逾一百七十五個市場 。產品線橫跨免疫學、腫瘤學、醫美、神經科學、眼科護理及其他專科。免疫學覆蓋風濕、皮膚與腸胃疾病；腫瘤學聚焦急性髓系、急性淋系、慢性淋系白血病及瀰漫性大B細胞淋巴瘤；神經領域涵括帕金森、偏頭痛、運動與精神障礙及阿茲海默；眼科護理面向慢性乾眼、青光眼、老年性視網膜退化與屈光不正；醫美業務提供 Botox Cosmetic、The Juvederm Collection of Fillers 等注射產品。管線中 NX-13 用於潰瘍性結腸炎與克隆氏病治療；CEL383 鎖定炎症性腸病；ALIA-1758 瞄準阿茲海默患者群體。
艾伯維簡介
公司代碼ABBV
公司名稱AbbVie Inc
上市日期Jan 02, 2013
CEOMichael (Robert A)
員工數量55000
證券類型Ordinary Share
年結日Jan 02
公司地址1 N Waukegan Rd
城市NORTH CHICAGO
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編60064
電話18479327900
網址https://www.abbvie.com/
公司代碼ABBV
上市日期Jan 02, 2013
CEOMichael (Robert A)
艾伯維公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
39.58K
+2.82%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
30.08K
+3.72%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
17.62K
+6.35%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Mr. Thomas J. (Tom) Falk
Mr. Thomas J. (Tom) Falk
Independent Director
Independent Director
5.32K
+21.01%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
39.58K
+2.82%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
常見問題
艾伯維的前五大股東是誰？
艾伯維的前五大股東如下：Dr. Azita Saleki-Gerhardt, Ph.D.
有多少機構持有艾伯維(ABBV)的股份？
截至2026Q1，共有5703家機構持有艾伯維的股份，合計持有的股份價值約為1.36B，占公司總股份的77.09% 。與2025Q4相比，機構持股有所增加，增幅為26641628.00。
哪個業務部門對艾伯維的收入貢獻最大？
在2026Q1，Immunology-SKYRIZI業務部門對艾伯維的收入貢獻最大，創收17.56B，占總收入的28.71% 。